The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis
Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-a...
Gespeichert in:
| Veröffentlicht in: | Dementia and geriatric cognitive disorders extra 2011-07, Vol.1 (1), p.212-227 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 227 |
|---|---|
| container_issue | 1 |
| container_start_page | 212 |
| container_title | Dementia and geriatric cognitive disorders extra |
| container_volume | 1 |
| creator | Lockhart, I.A. Orme, M.E. Mitchell, S.A. |
| description | Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. Results: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI –3.51, 95% confidence interval (CI) –5.75, –1.27], whereas this was not the case for memantine (WMD –1.65, 95% CI –4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (–1.86, 95% CI –5.71, 1.99; p = 0.34). Conclusion: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo. |
| doi_str_mv | 10.1159/000330032 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3199891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_04061d25b0a043b6abdb5721d8c8c79c</doaj_id><sourcerecordid>911928348</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-7227c6e3b53847a6e91ee701c8972cbde71b918f020eb24d31377be360dbc6fa3</originalsourceid><addsrcrecordid>eNptkstu1DAUhiMEolXpgj1CllggFgO-5WIWlYZ2gJGmooLp2nKck4lLYgc7M9V0xWvwbqx4EtxmGLUSiyixz_d_ObJPkjwn-C0hqXiHMWYsPvRRckiyjE9SnvHH974PkuMQriKG01RwwZ8mB5SSjFGeHSa_lw2gWV0brfQWuRotjAYboJrMbRU3B-MsugxwWzpzFnq4MS1StkLn0Ck7GAvo3Fk3NOBVbyCg2nm09BCTdoU-QKM2xq29GkMXYasb17pVVLfo27brB9eFOzl0EHUKGYsuYjguAro2Q4Om7U0DpgP_5-evgM5MABXgfQyHIbYwGI2-wsbA9a6rQU2mVrXbYMKz5Emt2gDHu_dRcvlxtjz9PFl8-TQ_nS4mmhMxTHJKc50BK1NW8FxlIAhAjokuRE51WUFOSkGKGlMMJeUVIyzPS2AZrkqd1YodJfPRWzl1JXtvOuW30ikj7zacX0nlY6MtSMxxRiqallhhzspMlVWZ5pRUhS50LnR0nYyufl12UMXLGOLhPZA-rFjTyJXbSEaEKASJgtc7gXc_1hAG2ZmgoW2VBbcOUhAiaMF4Eck3I6m9C8FDvf8LwfJ2tuR-tiL78n5be_LfJEXgxQh8V34Ffg_s86_-Wz6bzUZC9lXN_gKZEOQV</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>911928348</pqid></control><display><type>article</type><title>The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis</title><source>DOAJ Directory of Open Access Journals</source><source>Karger Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lockhart, I.A. ; Orme, M.E. ; Mitchell, S.A.</creator><creatorcontrib>Lockhart, I.A. ; Orme, M.E. ; Mitchell, S.A.</creatorcontrib><description>Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. Results: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI –3.51, 95% confidence interval (CI) –5.75, –1.27], whereas this was not the case for memantine (WMD –1.65, 95% CI –4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (–1.86, 95% CI –5.71, 1.99; p = 0.34). Conclusion: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo.</description><identifier>ISSN: 1664-5464</identifier><identifier>EISSN: 1664-5464</identifier><identifier>DOI: 10.1159/000330032</identifier><identifier>PMID: 22163246</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Alzheimer disease ; Behavioural medicine ; Behavioural/psychiatric symptoms of dementia ; Community Mental Health Services ; Geriatric psychiatry ; Home nursing ; Meta-analysis ; Original ; Original Research Article ; Preventive psychiatry ; Systematic reviews</subject><ispartof>Dementia and geriatric cognitive disorders extra, 2011-07, Vol.1 (1), p.212-227</ispartof><rights>2011 S. Karger AG, Basel</rights><rights>Copyright © 2011 by S. Karger AG, Basel 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-7227c6e3b53847a6e91ee701c8972cbde71b918f020eb24d31377be360dbc6fa3</citedby><cites>FETCH-LOGICAL-c419t-7227c6e3b53847a6e91ee701c8972cbde71b918f020eb24d31377be360dbc6fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199891/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199891/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27635,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22163246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lockhart, I.A.</creatorcontrib><creatorcontrib>Orme, M.E.</creatorcontrib><creatorcontrib>Mitchell, S.A.</creatorcontrib><title>The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis</title><title>Dementia and geriatric cognitive disorders extra</title><addtitle>Dement Geriatr Cogn Disord Extra</addtitle><description>Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. Results: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI –3.51, 95% confidence interval (CI) –5.75, –1.27], whereas this was not the case for memantine (WMD –1.65, 95% CI –4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (–1.86, 95% CI –5.71, 1.99; p = 0.34). Conclusion: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo.</description><subject>Alzheimer disease</subject><subject>Behavioural medicine</subject><subject>Behavioural/psychiatric symptoms of dementia</subject><subject>Community Mental Health Services</subject><subject>Geriatric psychiatry</subject><subject>Home nursing</subject><subject>Meta-analysis</subject><subject>Original</subject><subject>Original Research Article</subject><subject>Preventive psychiatry</subject><subject>Systematic reviews</subject><issn>1664-5464</issn><issn>1664-5464</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>DOA</sourceid><recordid>eNptkstu1DAUhiMEolXpgj1CllggFgO-5WIWlYZ2gJGmooLp2nKck4lLYgc7M9V0xWvwbqx4EtxmGLUSiyixz_d_ObJPkjwn-C0hqXiHMWYsPvRRckiyjE9SnvHH974PkuMQriKG01RwwZ8mB5SSjFGeHSa_lw2gWV0brfQWuRotjAYboJrMbRU3B-MsugxwWzpzFnq4MS1StkLn0Ck7GAvo3Fk3NOBVbyCg2nm09BCTdoU-QKM2xq29GkMXYasb17pVVLfo27brB9eFOzl0EHUKGYsuYjguAro2Q4Om7U0DpgP_5-evgM5MABXgfQyHIbYwGI2-wsbA9a6rQU2mVrXbYMKz5Emt2gDHu_dRcvlxtjz9PFl8-TQ_nS4mmhMxTHJKc50BK1NW8FxlIAhAjokuRE51WUFOSkGKGlMMJeUVIyzPS2AZrkqd1YodJfPRWzl1JXtvOuW30ikj7zacX0nlY6MtSMxxRiqallhhzspMlVWZ5pRUhS50LnR0nYyufl12UMXLGOLhPZA-rFjTyJXbSEaEKASJgtc7gXc_1hAG2ZmgoW2VBbcOUhAiaMF4Eck3I6m9C8FDvf8LwfJ2tuR-tiL78n5be_LfJEXgxQh8V34Ffg_s86_-Wz6bzUZC9lXN_gKZEOQV</recordid><startdate>20110720</startdate><enddate>20110720</enddate><creator>Lockhart, I.A.</creator><creator>Orme, M.E.</creator><creator>Mitchell, S.A.</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20110720</creationdate><title>The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis</title><author>Lockhart, I.A. ; Orme, M.E. ; Mitchell, S.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-7227c6e3b53847a6e91ee701c8972cbde71b918f020eb24d31377be360dbc6fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Alzheimer disease</topic><topic>Behavioural medicine</topic><topic>Behavioural/psychiatric symptoms of dementia</topic><topic>Community Mental Health Services</topic><topic>Geriatric psychiatry</topic><topic>Home nursing</topic><topic>Meta-analysis</topic><topic>Original</topic><topic>Original Research Article</topic><topic>Preventive psychiatry</topic><topic>Systematic reviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lockhart, I.A.</creatorcontrib><creatorcontrib>Orme, M.E.</creatorcontrib><creatorcontrib>Mitchell, S.A.</creatorcontrib><collection>Karger Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Dementia and geriatric cognitive disorders extra</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lockhart, I.A.</au><au>Orme, M.E.</au><au>Mitchell, S.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis</atitle><jtitle>Dementia and geriatric cognitive disorders extra</jtitle><addtitle>Dement Geriatr Cogn Disord Extra</addtitle><date>2011-07-20</date><risdate>2011</risdate><volume>1</volume><issue>1</issue><spage>212</spage><epage>227</epage><pages>212-227</pages><issn>1664-5464</issn><eissn>1664-5464</eissn><abstract>Background/Aims: Behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine to manage BPSD within their licensed indications in AD were compared. Methods: A systematic review, random effects meta-analysis and Bucher indirect comparison were conducted. Results: Six randomised controlled studies (4 donepezil and 2 memantine) reported use within the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analysis. BPSD showed significant improvement with donepezil compared with placebo [weighted mean difference (WMD) in NPI –3.51, 95% confidence interval (CI) –5.75, –1.27], whereas this was not the case for memantine (WMD –1.65, 95% CI –4.78, 1.49). WMD in NPI for donepezil versus memantine favoured donepezil but was not statistically significant (–1.86, 95% CI –5.71, 1.99; p = 0.34). Conclusion: Within its licensed indication, donepezil is efficacious for the management of BPSD in AD compared with placebo.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>22163246</pmid><doi>10.1159/000330032</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1664-5464 |
| ispartof | Dementia and geriatric cognitive disorders extra, 2011-07, Vol.1 (1), p.212-227 |
| issn | 1664-5464 1664-5464 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3199891 |
| source | DOAJ Directory of Open Access Journals; Karger Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Alzheimer disease Behavioural medicine Behavioural/psychiatric symptoms of dementia Community Mental Health Services Geriatric psychiatry Home nursing Meta-analysis Original Original Research Article Preventive psychiatry Systematic reviews |
| title | The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A18%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Efficacy%20of%20Licensed-Indication%20Use%20of%20Donepezil%20and%20Memantine%20Monotherapies%20for%20Treating%20Behavioural%20and%20Psychological%20Symptoms%20of%20Dementia%20in%20Patients%20with%20Alzheimer%E2%80%99s%20Disease:%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Dementia%20and%20geriatric%20cognitive%20disorders%20extra&rft.au=Lockhart,%20I.A.&rft.date=2011-07-20&rft.volume=1&rft.issue=1&rft.spage=212&rft.epage=227&rft.pages=212-227&rft.issn=1664-5464&rft.eissn=1664-5464&rft_id=info:doi/10.1159/000330032&rft_dat=%3Cproquest_pubme%3E911928348%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=911928348&rft_id=info:pmid/22163246&rft_doaj_id=oai_doaj_org_article_04061d25b0a043b6abdb5721d8c8c79c&rfr_iscdi=true |